Previous Close | 26.00 |
Open | 26.16 |
Bid | 25.99 x 300 |
Ask | 26.12 x 300 |
Day's Range | 25.87 - 27.31 |
52 Week Range | 6.40 - 30.27 |
Volume | |
Avg. Volume | 1,262,638 |
Market Cap | 2.248B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Key Clinical Trials Show Promise as Company Strengthens Financial Position
Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of the company on March 1, 2024, according to a recent SEC Filing.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]